Lisata Therapeutics Inc. (LSTA) - Market Cap to Net Income Ratio

Lisata Therapeutics Inc. - graphic logo of issuer LSTA

Lisata Therapeutics adheres to basic environmental standards, limiting its efforts to reagent disposal and energy conservation. Asset value growth is driven by the CendR platform's success in treating pancreatic tumors and acquisition prospects, with the indicator standing at -0.80. The stock price history clearly links these factors to current developments. The company is also developing partnerships with clinics to implement methods for increasing the permeability of neoplasms.

LSTA lisata.com: Price to Earnings Ratio in the range 04/28/2023 - 11/15/2026

Analytical breakdowns for Lisata Therapeutics

- market price and analyst price targets:
Market Price Lisata Therapeutics|LSTA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Lisata Therapeutics, Inc.|LSTA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Lisata Therapeutics|LSTA - Company Net Assets|Market Value to Book Value lisata.com|LSTA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Lisata Therapeutics|LSTA - Long-Term Debt to Equity|Short-Term Debt to Equity Lisata Therapeutics|LSTA - Company Aggregate Debts|Debts to Book Capitalization Lisata Therapeutics, Inc.|LSTA - Company Long-Term Liabilities|Amount of Current Liabilities Lisata Therapeutics|Critical Liquidity Ratio lisata.com
- business earnings and investment ratios data:
LSTA - Company Net Income|Expected Net Profit Lisata Therapeutics|LSTA - Price to Earnings Ratio|Future Price to Earnings Multiple lisata.com|LSTA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Lisata|LSTA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Lisata Therapeutics|LSTA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lisata.com|LSTA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Lisata Therapeutics
- issuer revenue and sales details:
LSTA - Company Revenue|Company Future Sales Lisata Therapeutics|LSTA - P/S Multiple|Forward P/S Multiple Lisata Therapeutics, Inc.|LSTA - Revenue Growth YoY (Last 12 Months)
Summary company analysis:LSTA, Lisata
Manufactured products of Lisata

The P/E ratio reflects the cost of one unit of net profit, allowing an investor to estimate the investment payback period by comparing market capitalization with the business's actual earnings. By analyzing the issuer's P/E ratio, one can understand how the market values the potential of the L CendR platform and the synergy of Lisata Therapeutics (LSTA) strategic alliances in developing therapies for solid tumors.

Competing companies

Market Cap to Earnings Geron GERN|P/E Multiple NBTX|Bicycle Therapeutics (BCYC) - Market Cap to Net Income Ratio|CytomX Pharma - Price to Earnings Ratio|perspectivetherapeutics.com (CATX) - Market Cap to Earnings|GNLX: Price to Earnings Ratio|Company Value to Net Income MOLN (Molecular Partners Ltd)|Oncolytics Biotech (ONCY) - Price to Earnings Ratio|Market Cap to Net Income MBRX (Moleculin)|Price to Earnings Ratio Galera Therapeutics|Price to Earnings Ratio MTEM